We note that numerous studies have demonstrated that treatment with the TBK1/IKKε inhibitor amlexanox ameliorates hepatic steatosis, inflammation, and fibrosis in MASLD models34–38. The gene discussed is TBK1; the disease is metabolic dysfunction-associated steatotic liver disease.